Dynorphin B and spinal analgesia: Induction of antinociception by the cannabinoids CP55,940, Δ9-THC and anandamide

Brain Research

Volumn 857, Issue 1-2, 2000, Pages 337-342

  Houser, Susan J ^a   Eads, Micah ^a   Embrey, James P ^a   Welch, Sandra P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Anandamide; Antinociception; Cannabinoid; Dynorphin A; Dynorphin B; Rat

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID; DRONABINOL; DYNORPHIN B;

ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SPINAL ANESTHESIA; SPINAL CORD; TAIL FLICK TEST;

ANALGESIA; ANALGESICS; ANALGESICS, NON-NARCOTIC; ANIMALS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; CANNABINOIDS; CYCLOHEXANOLS; DYNORPHINS; ENDOCANNABINOIDS; ENDORPHINS; MALE; PAIN; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; TETRAHYDROCANNABINOL;

EID: 0033955624     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)01981-8     Document Type: Article

References (41)

1. Akil H., Watson S.J., Young E., Lewis M.E., Khachaturian H., Walker J.M. Endogenous opioids: Biology and function. Annu. Rev. Neurosci. 7:1984;223-255.
2. Butelman E.R., France C.P., Woods J.H. Agonist and antagonist effects of dynorphin A (1-13) in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1995;374-380.
3. Chavkin C., James I., Goldstein A. Dynorphin is a specific endogenous ligand for the kappa opioid receptor. Science. 215:1982;413-415.
4. Cichewicz D.L., Martin Z., Smith F.L., Welch S.P. Enhancement of opioid potency with inactive oral administration of Δ9-THC: Dose-response analysis and receptor characterization. J. Pharmacol. Exp. Ther. 289:1999;859-867.
5. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharm. Exp. Ther. 72:1941;74-79.
6. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
7. 9 tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. Eur. J. Pharmacol. 12:1970;382-384.
8. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, and endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
9. 9-THC. J. Pharmacol. Exp. Ther. 272:1995;699-707.
10. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
11. Han J.S., Xie C.W. Dynorphin: Potent analgesic effect in spinal cord of the rat. Life Sci. 31:1982;1781-1784.
12. Harris L.S., Pierson A.K. Some narcotic antagonists in the benzomorphan series. J. Pharm. Exp. Ther. 143:1990;141-148.
13. Hollt V. Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Tox. 26:1986;59-77.
14. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
15. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20:1999;287-294.
16. D.L. Mason, S.P. Welch, A diminution of Δ9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development, Eur. J. Pharmacol. (1999) in press.
17. D.J. Mason, S.P. Welch, Cannabinoid modulation of dynorphin A: Correlation to cannabinoid-induced antinociception, Eur. J. Pharmacol. (1999) in press.
18. Matsuda L.A., Lolait S.J., Bowstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
19. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
20. Nylander I., Tan-No K., Winter A., Silsberring J. Processing of prodynorphin-derived peptides in striatal extracts. Identification by electrospray ionization mass spectrometry linked to size-exclusion chromatography. Life Sci. 57:1995;123-129.
21. Pertwee R., Griffin G., Hanus L., Mechoulam R. Effects of two fatty acid ethanolamides on mouse vasa deferentia. Eur. J. Pharmacol. 259:1994;115-120.
22. Pugh G.J., Mason D.J., Combs V., Welch S.P. Involvement of dynorphin B in the antinociceptive effects of CP55,940, in the spinal cord. J. Pharm. Exp. Ther. 281:1997;730-737.
23. 9-THC and morphine in the spinal cord. J. Pharm. Exp. Ther. 279:1996;608-616.
24. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., LeFur G. SR141716A, a potent and selective antagonist of the cannabinoid receptor. Fed. Eur. Biochem. Soc. Lett. 350:1994;240-244.
25. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., LeFur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
26. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of Δ9-tetrahydrocannabinol and anandamide antinociception in non-arthritic and arthritic rats. Pharmacol. Biochem. Behav. 60:1998;183-191.
27. Smith F.L., Stevens D.L., Martin Z.L., Welch S.P. The enhancement of morphine antinociception by Δ9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 60:1998;559-566.
28. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharm. Exp. Ther. 270:1994;219-227.
29. 9 tetrahydrocannabinol and kappa opioids in mice J. Pharmacol. Exp. Ther. 268:1994;1382-1387.
30. Song Z.H., Takemori A.E. Involvement of spinal kappa opioid receptors in the antagonistic effect of dynorphins on morphine antinociception. Life Sci. 48:1991;1447-1453.
31. Spampinato S., Romualdi P., Candeletti S., Cavicchini E., Ferri S. Distinguishable effects of intrathecal dynorphins, somatostatin, neurotensin, and s-calcitonin nociception and motor function in the rat. Pain. 35:1988;94-104.
32. Stevens C.W., Yaksh T.L. Dynorphin A and related peptides administered intrathecally in the rat: A search for putative kappa receptor activity. J. Pharmacol. Exp. Ther. 238:1986;833-838.
33. Tseng L.F. Intracerebroventricular administration of beta-endorphin releases immunoreactive methionine enkephalin from the spinal cord of cats, guinea pigs and mice. Neuropharmacology. 28:1989;1333-1339.
34. Tseng L.F., Collins K.A. Spinal involvement of both dynorphin A and met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse. J. Pharmacol. Exp. Ther. 266:1993;1430-1438.
35. Welch S.P. Modulation of cannabinoid-induced antinociception by nor-binaltorphimine, but not ICI 174,864, in mice. J. Pharmacol. Exp. Ther. 265:1993;633-640.
36. Welch S.P. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Dep. 45:1997;39-45.
37. 9-THC-induced antinociception. J. Pharm. Exp. Ther. 273:1995;1235-1244.
38. S.P. Welch, M. Eads, Synergistic interactions of endogenous opioids and cannabinoid systems, Brain Res. (1999) in press.
39. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception following intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
40. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally-administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262:1992;10-18.
41. Xie C.W., Tang J., Han J.S. Clonidine-stimulated the release of dynorphin in the spinal cord of the rat: A possible mechanism for its depressor effects. Neurosci. Lett. 65:1986;244-248.